Atrion (NASDAQ:ATRI) Rating Lowered to Sell at StockNews.com

Atrion (NASDAQ:ATRI) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday.

Atrion Stock Performance

Shares of Atrion stock opened at $405.29 on Monday. Atrion has a one year low of $274.98 and a one year high of $643.48. The company has a market cap of $713.31 million, a price-to-earnings ratio of 36.74 and a beta of 0.60. The business’s 50 day moving average price is $402.59 and its 200 day moving average price is $364.60.

Atrion (NASDAQ:ATRI) last announced its quarterly earnings data on Thursday, February 29th. The medical instruments supplier reported $3.65 EPS for the quarter. Atrion had a return on equity of 8.07% and a net margin of 11.46%. The firm had revenue of $43.58 million for the quarter.

Institutional Investors Weigh In On Atrion

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Copeland Capital Management LLC raised its position in Atrion by 56.4% in the fourth quarter. Copeland Capital Management LLC now owns 86 shares of the medical instruments supplier’s stock valued at $33,000 after purchasing an additional 31 shares during the period. Quadrant Capital Group LLC acquired a new stake in shares of Atrion in the fourth quarter valued at $36,000. Harbor Investment Advisory LLC grew its stake in shares of Atrion by 33.1% in the fourth quarter. Harbor Investment Advisory LLC now owns 189 shares of the medical instruments supplier’s stock valued at $72,000 after buying an additional 47 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Atrion by 592.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 270 shares of the medical instruments supplier’s stock valued at $102,000 after buying an additional 231 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of Atrion in the fourth quarter valued at $108,000. Hedge funds and other institutional investors own 66.19% of the company’s stock.

Atrion Company Profile

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.